September 14, 2010 by staff
Arna, ARNA is down. Arena Pharmaceuticals Inc. (NASDAQ: ARNA) shares dive by 39.85 percent and is currently being operated on and 4.12. It’s stock today is the formation of craters in a news leak that says FDA drug weight loss called Lorcaserin Arena is only effective “by a narrow margin.”
A release is expected on Thursday by the Food and Drug Administration U.S. Lorcaserin on the results of Arna. Friday morning at 7:00 am EST, ARNA is that the conclusion of a webcast to discuss the ruling.
Until now, the trading of options are varied. Report at 9:50 ET have details of 40,000 calls and puts trade 29,000.
The ARNA or Arena Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of oral drugs. The company targets G protein-coupled receptor (GPCR), in four major therapeutic areas: cardiovascular, central nervous, inflammatory and metabolic diseases.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.